Evidence map›Paper›PMID 41824001›Full record

ArticleJournal of medicinal chemistry2026

Zwitterionic Modification of PSMA Ligands Reduces Off-Target Binding and Tissue Retention.

Lennart F V Spickschen, Roland Thünauer, Aleksander J Swierzewski, John M Van Wazer, Amanda Fears, Matthew D Silva, Daniel L J Thorek, Elke Oetjen, Wolfgang Maison

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lennart F V SpickschenDepartment of Chemistry, Institute of Pharmacy, University of Hamburg, Bundesstrasse 45, Hamburg 20146, Germany.
Roland ThünauerTechnology Platform Light Microscopy (TPLM), University of Hamburg and Advanced Light and Fluorescence Microscopy (ALFM) Facility, Centre of Structural Systems Biology, Notkestrasse 85, Hamburg 22607, Germany.
Aleksander J SwierzewskiDepartment of Chemistry, Institute of Pharmacy, University of Hamburg, Bundesstrasse 45, Hamburg 20146, Germany.
John M Van WazerDepartment of Radiology, Washington University, School of Medicine, 510 S. Kingshighway Blvd., Saint Louis, Missouri 63110, United States.ORCID 0009-0008-1645-2382
Amanda FearsDepartment of Radiology, Washington University, School of Medicine, 510 S. Kingshighway Blvd., Saint Louis, Missouri 63110, United States.
Matthew D SilvaEMIT Imaging, Inc.12 Michigan Drive, Natick, Massachusetts 01760, United States.
Daniel L J ThorekDepartment of Radiology, Washington University, School of Medicine, 510 S. Kingshighway Blvd., Saint Louis, Missouri 63110, United States.ORCID 0000-0003-2437-1239
Elke OetjenInstitute of Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Wolfgang MaisonDepartment of Chemistry, Institute of Pharmacy, University of Hamburg, Bundesstrasse 45, Hamburg 20146, Germany.ORCID 0000-0003-2793-5722

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Off-target tissue retention is a serious limitation for prostate-specific membrane antigen (PSMA)-targeted drugs. This study addresses key questions regarding the role of zwitterionic modifications in PSMA-ligand design for tissue distribution. A series of fluorescent PSMA-ligands was synthesized and evaluated with respect to PSMA-binding, tumor uptake, and biodistribution in cell experiments and in mice. The data revealed that the introduction of two zwitterionic groups into the linker domain of the PSMA-specific conjugates was particularly advantageous. The resulting compound

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIAnimalsCell Line, TumorHumansLigandsMaleMiceProstatic NeoplasmsTissue DistributionAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILigandsoff-target toxicityprostate cancerPSMA-617PSMA targetingzwitterions

Identifiers

PMID41824001
PMCPMC13036764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.